Entrada Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

TRDA$5.25+11.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Collaboration revenue	$94,694	$18,170	$153,814	$43,430
Operating expenses:
Research and development	32,035	26,300	$60,643	49,402
General and administrative	9,236	8,169	18,635	16,107
Total operating expenses	41,271	34,469	79,278	65,509
Income (loss) from operations	53,423	(16,299)	74,536	(22,079)
Other income:
Interest and other income	4,366	4,218	8,580	6,875
Total other income	4,366	4,218	8,580	6,875
Income (loss) before provision for income taxes	57,789	(12,081)	83,116	(15,204)
Provision for income taxes	(2,758)	(13,847)	$(4,589)	(17,398)
Net income (loss)	$55,031	$(25,928)	$78,527	$(32,602)
Net income (loss) per share, basic	$1.61	$(0.78)	$2.32	$(0.99)
Net income (loss) per share, diluted	$1.55	$(0.78)	$2.23	$(0.99)
Weighted‑average common shares outstanding, basic	34,180,549	33,163,320	33,838,811	32,770,989
Weighted‑average common shares outstanding, diluted	35,507,029	33,163,320	35,148,221	32,770,989
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	(83)	(363)	(524)	1,052
Total other comprehensive (loss) income	(83)	(363)	(524)	1,052
Total comprehensive income (loss)	$54,948	$(26,291)	$78,003	$(31,550)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.